Previous 10 | Next 10 |
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44 th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET. A live webcast of the panel presentation will...
2024-01-30 13:04:10 ET Summary GlycoMimetics is developing molecules that target specific carbohydrate groups in the treatment of cancer. The company's most advanced project, Uproleselan, has recently shown promising results in a phase 1b/2 study for patients with secondary AML. ...
2024-01-04 16:19:31 ET Gainers: Molecular Partners ( MOLN ) +14% . Sutro Biopharma ( STRO ) +9% . Ribbon Communications ( RBBN ) +7% . Resources Connection ( RGP ) +7% . Pyxis Oncology ( PYXS ) +6% . Losers: 89bio ( ETN...
First in human trial evaluating highly potent E-selectin antagonist, GMI-1687, met its primary and secondary endpoints with no dose-limiting toxicities or safety signals Single ascending dose study confirmed that subcutaneous dosing generated linear pharmacokinetics and achieved target plasma...
FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced the completion of enrollmen...
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of Hematology (ASH) Annual Meeting will feature two presentations on uproleselan...
2023-11-27 18:51:52 ET Summary GlycoMimetics' uproleselan shows promise in AML, but Phase 3 trial changes introduce data interpretation and regulatory complexities. GlycoMimetics faces increased R&D and G&A expenses; financial health is stable short term but precarious lon...
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET. A live webcast of the fireside chat ...
2023-11-03 12:24:06 ET GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer Edwin Rock - Chief Medical Officer Brian Ha...
2023-11-03 07:11:37 ET More on GlycoMimetics GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem GlycoMimetics chief medical officer Rock buys 65.4K shares Seeking Alpha’s Quant Rating on GlycoMimetics Historical earnings...
News, Short Squeeze, Breakout and More Instantly...
2024-06-26 06:35:00 ET A Short Guide to Different Order Types With Penny Stocks Understanding the various order types can significantly enhance your strategy when trading penny stocks. Penny stocks represent an exciting opportunity for investors seeking to enter the stock market at ...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 6.8% to $126.09 on volume of 414,790,976 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 18.7% to $0.265 on volume of 162,165,405 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 12.6%...
A look at the top 10 most actives in the United States GlycoMimetics Inc. (GLYC) rose 42.5% to $0.38 on volume of 73,016,681 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.16 on volume of 71,818,174 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 25.4% to $0.2431 on volume...